Patents by Inventor Jeffery Haines

Jeffery Haines has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11891618
    Abstract: Non-human animal cells and non-human animals comprising a humanized TTR locus comprising a beta-slip mutation and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TTR locus comprising a beta-slip mutation express a human transthyretin protein or a chimeric transthyretin protein, fragments of which are from human transthyretin. Methods are provided for using such non-human animals comprising a humanized TTR locus to assess in vivo efficacy of human-TTR-targeting reagents such as nuclease agents designed to target human TTR.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: February 6, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jeffery Haines, Keith Crosby, Meghan Drummond Samuelson, David Frendewey, Brian Zambrowicz, Andrew J. Murphy
  • Publication number: 20230257432
    Abstract: Tau reporter compositions, tau reporter cells, and tau reporter animals are provided that comprise a four-repeat (4R) tau isoform linked to a first reporter protein and a three-repeat (3R) tau isoform linked to a second reporter protein that is different from the first reporter protein. Methods are provided for making such tau reporter cells and tau reporter animals and for using such tau reporter cells and tau reporter animals for assessing the activity of tau-targeting reagents.
    Type: Application
    Filed: February 10, 2023
    Publication date: August 17, 2023
    Inventors: Jeffery Haines, Keith Crosby
  • Publication number: 20230102342
    Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TTR locus comprising a V30M mutation and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TTR locus express a human TTR protein or a chimeric TTR protein, fragments of which are from human TTR. Methods are provided for using such non-human animals comprising a humanized TTR locus to assess in vivo efficacy of human-TTR-targeting reagents such as nuclease agents designed to target human TTR.
    Type: Application
    Filed: March 23, 2021
    Publication date: March 30, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Meghan Drummond Samuelson, Jeffery Haines, Charleen Hunt, Guochun Gong, Brian Zambrowicz
  • Publication number: 20230078551
    Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TTR locus and methods of using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TTR locus express a human transthyretin protein or a chimeric transthyretin protein, fragments of which are from human transthyretin. Methods are provided for using such non-human animals comprising a humanized TTR locus to assess in vivo efficacy of human-TTR-targeting reagents such as nuclease agents designed to target human TTR. Methods are also provided for making such non-human animals comprising a humanized TTR locus.
    Type: Application
    Filed: November 22, 2022
    Publication date: March 16, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Meghan Drummond Samuelson, Jeffery Haines, Suzanne Hartford, David Frendewey, Brian Zambrowicz, Andrew J. Murphy
  • Publication number: 20200385760
    Abstract: Non-human animal cells and non-human animals comprising a humanized TTR locus comprising a beta-slip mutation and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TTR locus comprising a beta-slip mutation express a human transthyretin protein or a chimeric transthyretin protein, fragments of which are from human transthyretin. Methods are provided for using such non-human animals comprising a humanized TTR locus to assess in vivo efficacy of human-TTR-targeting reagents such as nuclease agents designed to target human TTR.
    Type: Application
    Filed: June 3, 2020
    Publication date: December 10, 2020
    Inventors: Jeffery Haines, Keith Crosby, Meghan Drummond-Samuelson, David Frendewey, Brian Zambrowicz, Andrew J. Murphy
  • Publication number: 20190098879
    Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TTR locus and methods of using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TTR locus express a human transthyretin protein or a chimeric transthyretin protein, fragments of which are from human transthyretin. Methods are provided for using such non-human animals comprising a humanized TTR locus to assess in vivo efficacy of human-TTR-targeting reagents such as nuclease agents designed to target human TTR. Methods are also provided for making such non-human animals comprising a humanized TTR locus.
    Type: Application
    Filed: September 28, 2018
    Publication date: April 4, 2019
    Inventors: Meghan Drummond-Samuelson, Jeffery Haines, Suzanne Hartford, David Frendewey, Brian Zambrowicz, Andrew J. Murphy